Cibus, Inc. CBUS
Cibus is a leading agricultural biotechnology company that primarily uses proprietary gene editing technologies to develop plant traits, which are specific genetic characteristics in the DNA of a plant's seed. Plant traits, or characteristics, influence how a resulting plant functions and/or interacts with its environment. Cibus produces these edited plant traits by a unique process that is endeavoring to change the scale and speed of plant breeding for many major agricultural crops. Over the course of its history, Cibus has developed a proprietary time bound and predictable gene editing platform referred to as the Rapid Trait Development System™ (RTDS®). This system allows Cibus to edit gene targets that are the basis of novel traits that can be integrated into Cibus' customers' best or elite seed genetics in as
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M | $4.3M | $1.8M | $157.0K | $26.0M | $23.9M | $7.3M | $236.0K | $508.0K | $399.0K |
| Cost of revenue | — | — | — | $0 | $28.6M | $35.1M | $9.3M | — | — | $200.0K |
| Gross profit | — | — | — | $157.0K | -$2.6M | -$11.3M | -$2.0M | $236.0K | $508.0K | $199.0K |
| R&D | $44.2M | $50.4M | $42.4M | $11.6M | $11.3M | $11.1M | $12.2M | $10.4M | $11.5M | $5.6M |
| SG&A | $26.9M | $30.8M | $28.9M | $11.0M | — | $16.2M | $19.0M | $13.4M | $11.6M | $6.7M |
| Total operating expenses | $101.2M | $262.7M | $320.7M | $22.5M | $26.8M | $32.6M | $37.7M | $28.4M | $26.3M | $12.5M |
| Operating income | -$97.5M | -$258.4M | -$318.9M | -$22.4M | -$29.3M | -$43.8M | -$39.7M | -$28.1M | -$25.8M | -$12.1M |
| Interest expense | — | — | — | $75.0K | $1.4M | $1.4M | $1.5M | $1.3M | $261.0K | $5.0K |
| Pre-tax income | -$132.2M | -$282.7M | -$337.6M | -$16.9M | -$29.2M | -$44.8M | -$39.6M | -$27.9M | -$26.0M | -$12.1M |
| Income tax | $29.0K | $29.0K | $4.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$132.2M | -$282.7M | -$337.6M | -$16.9M | -$29.2M | -$44.8M | -$39.6M | -$27.9M | -$26.0M | -$12.1M |
| EPS, basic | -2.78 | -10.83 | -25.95 | -18.36 | -0.78 | -1.32 | — | — | — | — |
| EPS, diluted | -2.78 | -10.83 | -25.95 | -18.36 | -0.78 | -1.32 | -1.21 | -0.91 | -1.12 | -0.62 |
| Shares, diluted (wtd. avg.) | 45.8M | 23.2M | 10.3M | 919,959 | 37.5M | 33.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.9M | $14.4M | $32.7M | $3.5M | $14.4M | $18.3M | $60.0M | $95.3M | $56.7M | $5.0M |
| Short-term investments | — | — | — | $0 | $0 | $11.7M | $0 | — | — | — |
| Receivables | $503.0K | $1.0M | $500.0K | $0 | $0 | $4.9M | $1.1M | — | $0 | $110.0K |
| Inventory | — | — | — | — | $0 | $1.4M | $2.6M | — | — | — |
| Total current assets | $12.1M | $16.9M | $35.2M | $4.1M | $15.2M | $39.6M | $63.5M | $95.5M | $57.5M | $5.5M |
| Property, plant and equipment | — | — | — | $4.5M | $21.7M | $22.9M | $23.2M | $21.9M | $14.4M | $11.0M |
| Goodwill | $232.5M | $253.5M | $434.9M | $0 | — | — | — | — | — | — |
| Other intangibles | $31.7M | $33.6M | $35.4M | $158.0K | — | — | — | — | — | — |
| Total assets | $305.0M | $350.1M | $544.4M | $22.4M | $37.2M | $63.3M | $88.1M | $118.8M | $72.2M | $16.6M |
| Accounts payable | $8.1M | $6.0M | $6.1M | $340.0K | $1.3M | $929.0K | $1.1M | $818.0K | $1.0M | $357.0K |
| Short-term debt | $435.0K | $436.0K | $833.0K | $0 | — | — | — | — | — | — |
| Total current liabilities | $16.9M | $19.9M | $21.3M | $1.7M | $4.9M | $6.9M | $7.2M | $7.0M | $4.3M | $2.9M |
| Long-term debt | $93.0K | $226.0K | $536.0K | $0 | $0 | $1.5M | — | — | — | — |
| Total liabilities | $283.2M | $252.2M | $206.1M | $15.2M | $23.1M | $26.5M | $25.6M | $25.4M | $14.7M | $3.5M |
| Retained earnings | -$858.3M | -$731.2M | -$479.8M | -$212.2M | -$196.1M | -$166.9M | -$122.1M | -$82.4M | -$54.5M | -$28.6M |
| Total equity | $21.8M | $92.2M | $293.5M | $7.2M | $14.1M | $36.9M | $62.5M | $93.4M | $57.5M | $13.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$50.6M | -$58.0M | -$46.2M | -$19.4M | -$18.8M | -$43.7M | -$32.0M | -$20.2M | -$12.8M | -$9.2M |
| Depreciation and amortisation | $5.9M | $6.9M | $4.7M | $1.5M | $2.3M | $1.9M | $1.6M | $1.1M | $551.0K | $345.0K |
| Stock-based compensation | $8.2M | $10.8M | $16.1M | $4.0M | $2.1M | $5.0M | $9.2M | $4.4M | $12.1M | $948.0K |
| Capital expenditure | $578.0K | $808.0K | $4.3M | $1.5M | $497.0K | $1.8M | $3.0M | $1.8M | $779.0K | $10.4M |
| Investing cash flow | -$578.0K | -$808.0K | $55.1M | -$1.5M | $11.2M | -$13.5M | -$3.0M | -$1.8M | -$779.0K | -$10.4M |
| Financing cash flow | $46.6M | $40.6M | $20.3M | $10.0M | $3.7M | $15.4M | -$330.0K | $60.7M | $65.2M | — |
| Buybacks | — | — | — | — | — | — | $800.0K | $200.0K | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-026011.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $399.0K | $508.0K | $236.0K | $7.3M | $23.9M | $26.0M | $157.0K | $1.8M | $4.3M | $3.6M |
| Gross profit | $199.0K | $508.0K | $236.0K | -$2.0M | -$11.3M | -$2.6M | $157.0K | — | — | — |
| Net income | -$12.1M | -$26.0M | -$27.9M | -$39.6M | -$44.8M | -$29.2M | -$16.9M | -$337.6M | -$282.7M | -$132.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2870
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CF | CF Industries Holdings, Inc. | $18.26B | 13.5x | 19.3% |
| MOS | MOSAIC CO | $5.67B | 10.5x | 8.4% |
| SMG | SCOTTS MIRACLE-GRO CO | $3.45B | 24.0x | -3.9% |
| UAN | CVR PARTNERS, LP | $1.33B | 13.4x | 15.4% |
| AVD | AMERICAN VANGUARD CORP | $30.4M | — | -5.9% |
| SNES | SenesTech, Inc. | $4.6M | — | 19.6% |
| BIOX | Bioceres Crop Solutions Corp. | — | — | -27.9% |
| EVGN | Evogene Ltd. | — | — | -30.9% |